Furthermore, in cases in which TKIs effectively target FLT3 ITD but select for AML subclones with FLT3 point mutations, including FLT3D835Y, resistant to first-generation as well as second-generation TKIs35–37, FLT3D835Y-mutation-specific TCR treatment could be combined with TKIs. Here, FLT3 is linked to acute myeloid leukemia.